<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04907019</url>
  </required_header>
  <id_info>
    <org_study_id>SY004005</org_study_id>
    <nct_id>NCT04907019</nct_id>
  </id_info>
  <brief_title>A Drug Interaction Study of SY-004 Capsules in Healthy Subjects</brief_title>
  <official_title>A Single Center, Open-label, Single Sequence Study to Evaluate the Potential Drug Interaction of CYP3A4 Inducer Rifampicin With SY-004 Capsules in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Yabao Pharmaceutical R&amp;D Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Yabao Pharmaceutical R&amp;D Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single center, open-label, single sequence study was conducted to evaluate the potential&#xD;
      drug interaction of CYP3A4 inducer rifampicin with SY-004 capsules in healthy subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>22 days</time_frame>
    <description>Peak Plasma Concentration (Cmax) of SY-004 when SY-004 capsules were treated with rifampicin alone or in combination with rifampicin at steady-state level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>22 days</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC0-t)) of SY-004 when SY-004 capsules were treated with rifampicin alone or in combination with rifampicin at steady-state level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>22 days</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC0-∞)) of SY-004 when SY-004 capsules were treated with rifampicin alone or in combination with rifampicin at steady-state level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>22 days</time_frame>
    <description>Peak Time （Tmax）of SY-004 when SY-004 capsules were treated with rifampicin alone or in combination with rifampicin at steady-state level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2z</measure>
    <time_frame>22 days</time_frame>
    <description>Half time （T1/2z）of SY-004 when SY-004 capsules were treated with rifampicin alone or in combination with rifampicin at steady-state level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLz/F</measure>
    <time_frame>22 days</time_frame>
    <description>Clearance (Clz/F)of SY-004 when SY-004 capsules were treated with rifampicin alone or in combination with rifampicin at steady-state level</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Group-drugs interaction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 subjects were enrolled in this study. The effects of rifampicin single dose and steady-state on the pharmacokinetics of sy-004 will be analyzed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifampicin，SY-004</intervention_name>
    <description>On the morning of D1, the subjects will take orally 80 mg of SY-004 Capsules on an empty stomach.Fasting will be performed within 4 hours after taking the medicine. From D8 to D14, the subjects will take orally 600 mg rifampicin before breakfast every day. On the day of D15, the subjects will take orally 600 mg rifampicin and 80 mg SY-004 Capsules on an empty stomach.&#xD;
From D16 to D21, subjects will take orally 600 mg of rifampicin before breakfast every day.The patient can be discharged from the hospital after completing the safety examination on D22.</description>
    <arm_group_label>Group-drugs interaction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subjects can communicate well with the researchers, understand and comply with the&#xD;
             requirements of this study, and sign the informed consent voluntarily.&#xD;
&#xD;
          -  Age on the day of signing the informed consent: healthy subjects aged 18 or above,&#xD;
             both male and female.&#xD;
&#xD;
          -  At the time of screening, male weight ≥ 50.0 kg, female weight ≥ 45.0 kg, 19.0 kg / m2&#xD;
             ≤ BMI ≤ 26.0 kg / m2.&#xD;
&#xD;
          -  Fasting blood glucose ≥ 3.9 mmol / L and &lt; 6.1 mmol / L.&#xD;
&#xD;
          -  From one month before the informed consent to three months after the last medication,&#xD;
             the subjects and their partners had no plans to have a child, take effective&#xD;
             contraceptive measures voluntarily, and donate sperm or eggs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Within 3 months before screening, a clinical trial was completed or withdrawn, or a&#xD;
             clinical trial was in progress, or participated in other medical trial activities, and&#xD;
             the researcher judged that it was not suitable to participate in this trial.&#xD;
&#xD;
          -  With a history of serious systemic diseases or family history (including&#xD;
             cardiovascular system, digestive system, urinary system, etc.), the researchers judged&#xD;
             that the disease status could significantly change the absorption, distribution,&#xD;
             metabolism and excretion of experimental drugs, or taking experimental drugs would&#xD;
             increase the risk of subjects.&#xD;
&#xD;
          -  Allergic constitution, or history of food allergy, or known allergy to study drug /&#xD;
             similar drug, or to rifampicin or rifamycin antibiotics.&#xD;
&#xD;
          -  Patients with previous orthostatic hypotension.&#xD;
&#xD;
          -  Those who had a history of drug abuse, drug abuse or positive urine drug screening&#xD;
             results in the past five years.&#xD;
&#xD;
          -  Those who donated blood or lost more than 400ml in 4 weeks before screening, or&#xD;
             received transfusion of blood or blood components in 4 weeks before screening, or&#xD;
             planned to donate blood components within 3 months after the end of the study.&#xD;
&#xD;
          -  Those who have a history of needle syncope or blood syncope, or who can't tolerate&#xD;
             venipuncture for blood collection, or who have difficulty in blood collection.&#xD;
&#xD;
          -  The patients with severe infection, trauma or major surgery within 4 weeks before the&#xD;
             screening, or who plan to perform surgery during the study period (including but not&#xD;
             limited to dental surgery).&#xD;
&#xD;
          -  Use any prescription, over-the-counter, herbal or health products within 2 weeks&#xD;
             before screening.&#xD;
&#xD;
          -  Any drugs that inhibit or induce liver drug metabolizing enzymes were used within 30&#xD;
             days before screening.&#xD;
&#xD;
          -  During the first three months of screening, the average alcohol intake was more than&#xD;
             14 units per week (1 unit = 360ml beer, 45ml spirits with 40% alcohol content or 150ml&#xD;
             wine), or those who could not give up drinking during the test period, or those with&#xD;
             positive alcohol breath.&#xD;
&#xD;
          -  Smoking more than 5 cigarettes per day within 3 months before screening, or unwilling&#xD;
             / unable to give up smoking during the trial.&#xD;
&#xD;
          -  Those who have special requirements for diet and can not comply with the unified diet&#xD;
             arrangement.&#xD;
&#xD;
          -  It is not guaranteed that chocolate, any food or drink containing caffeine or possibly&#xD;
             affecting the test results (such as pitaya, grapefruit, grapefruit, orange juice,&#xD;
             mango, etc.) will be fasted 48 hours before administration and during the test.&#xD;
&#xD;
          -  Pregnant or lactating women, or pregnancy test results were positive.&#xD;
&#xD;
          -  The screening results of HBsAg, HCV, TP and HIV were positive.&#xD;
&#xD;
          -  When screening, there was ALT &gt; 1.5 times the upper limit of normal value（ × ULN), or&#xD;
             ast &gt; 1.5 × ULN, or TBIL &gt; 1.5 × ULN。&#xD;
&#xD;
          -  When screening, the 12 lead ECG showed the following results: QT interval (qtcb) &gt;&#xD;
             450ms (male) or &gt; 470ms (female).&#xD;
&#xD;
          -  The results of physical examination, vital signs, abdominal B-ultrasound (liver,&#xD;
             gallbladder, pancreas, spleen and kidney), chest CT, ECG, laboratory examination items&#xD;
             and test related auxiliary examination in screening period were not suitable for the&#xD;
             participants.&#xD;
&#xD;
          -  According to the judgment of the researcher, the subjects with other factors not&#xD;
             suitable to participate in the experiment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 15, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug interactions，rifampicin， Hypoglycemic drugs</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

